Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer
Sabina Signoretti, … , Massimo Loda, Michele Pagano
Sabina Signoretti, … , Massimo Loda, Michele Pagano
Published September 1, 2002
Citation Information: J Clin Invest. 2002;110(5):633-641. https://doi.org/10.1172/JCI15795.
View: Text | PDF | Retraction
Article Oncology

Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer

  • Text
  • PDF
Abstract

Research Article

Authors

Sabina Signoretti, Lucia Di Marcotullio, Andrea Richardson, Sridhar Ramaswamy, Beth Isaac, Montserrat Rue, Franco Monti, Massimo Loda, Michele Pagano

×

Figure 3

Options: View larger image (or click on image) Download as PowerPoint
Correlation between Skp2 and proliferative index in sample set B. (a–d) ...
Correlation between Skp2 and proliferative index in sample set B. (a–d) Immunohistochemical stains of two representative breast carcinomas with anti-Skp2 (a and c) and anti-Ki67 (b and d) Ab’s. The tumor in the top row shows high Skp2/high Ki-67 levels. The one in the bottom row displays low Skp2/low Ki67 levels. (e) Graphic representation of the direct correlation between Skp2 expression and proliferative index in the 37 breast carcinomas. (f–k) Dual immunofluorescence of Skp2 with Ki67 in the breast cancer cell line MCF7 and in breast carcinomas. In MCF-7 cells (f, g, and h) as well as in breast carcinoma samples (i, j, and k), Skp2 protein (Texas Red) was detected only in cells expressing Ki67 (FITC). Both Ki67 and Skp2 are localized in the nucleus. A subset of cells that expressed Ki67 protein was negative for Skp2 expression (h and k).
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts